A 94-person intervention trial finds protein intake reduces blood pressure over a maltodextrin supplement.
A Dutch study on 94 overweight adults supports the growing notion that ample dietary protein may alleviate high blood pressure.
Researchers from the Top Institute of Food and Nutrition (Wageningen, the Netherlands) assigned 94 men and women to a protein (20 g of plant and animal protein) or maltodextrin supplement three times daily for four weeks. Diastolic and systolic blood pressure was evaluated periodically for patients, all of whom had elevated, but untreated blood pressure.
Blood pressure readings were evaluated as either office readings or daytime readings.
Compared to readings from the maltodextrin group, systolic blood pressure decreased by 4.9 mm Hg (office) and 4.6 mm Hg (daytime) in the protein group. Diastolic blood pressure dropped 2.7 mm Hg for the protein group over maltodextrin group (office), and daytime readings did not differ between groups.
Human risk of experiencing major cardiovascular events can be reduced with even slight drops in blood pressure, according to experts. The results of this protein trial complement previous intervention studies linking protein intake and blood pressure.
Agglomix (Tilburg, the Netherlands) provided protein and maltodextrin supplements for the study. It is available for further reading at the American Journal of Clinical Nutrition.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.